| Literature DB >> 33790336 |
Helen Earley1,2, Grainne Lennon3,4, J Calvin Coffey5, Desmond C Winter4, P Ronan O'Connell3,4.
Abstract
Butyrate is the primary energy source for colonocytes and is essential for mucosal integrity and repair. Butyrate deficiency as a result of colonic dysbiosis is a putative factor in ulcerative colitis (UC). Commensal microbes are butyrogenic, while others may inhibit butyrate, through hydrogenotropic activity. The aim of this study was to quantify butyrogenic and hydrogenotropic species and determine their relationship with inflammation within the colonic mucus gel layer (MGL). Mucosal brushings were obtained from 20 healthy controls (HC), 20 patients with active colitis (AC) and 14 with quiescent colitis (QUC). Abundance of each species was determined by RT-PCR. Inflammatory scores were available for each patient. Statistical analyses were performed using Mann-Whitney-U and Kruskall-Wallis tests. Butyrogenic R. hominis was more abundant in health than UC (p < 0.005), prior to normalisation against total bacteria. Hydrogenotropic B. wadsworthia was reduced in AC compared to HC and QUC (p < 0.005). An inverse correlation existed between inflammation and R. hominis (ρ - 0.460, p < 0.005) and B. wadsworthia (ρ - 0.646, p < 0.005). Other hydrogenotropic species did not widely colonise the MGL. These data support a role for butyrogenic bacteria in UC. Butyrate deficiency in UC may be related to reduced microbial production, rather than inhibition by microbial by-products.Entities:
Year: 2021 PMID: 33790336 PMCID: PMC8012382 DOI: 10.1038/s41598-021-86166-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
16S rRNA targeted PCR primer sequences used in this study and their expected amplicon sizes.
| Bacterial target | Forward Primer (5′–3′) | Reverse Primer (5′–3′) | Product Size (bp) | Concentration (nM) | References |
|---|---|---|---|---|---|
| CGC GTA GAT AAC CTG TCY TCA TG* | GTA GKA CGT GTG TAG CCC TGG TC | 1120 | 250 | [ | |
| GAT AAT CTG CCT TCA AGC CTG G | CYY YYY GCR RAG TCG STG CCC T* | 1150 | 250 | [ | |
| CGT GTG AAT AAT GCG AGG G | TCT CCG GTA CTC AAG CGT G | 207 | 200 | [ | |
| TAC TGC ATT GGA AAC TGT CG | CGG CAC CGA AGA GCA AT | 230 | 100 | [ |
*Denotes the use of a degenerate base pair. Y = C/T, R = A/G, S = C/G, W = A/T, K = G/T.
Figure 1Schematic representing work flow through sample collection to data analysis.
Summary of characteristics of individuals in each cohort.
| HC | QUC | AC | ||
|---|---|---|---|---|
| n | 20 | 14 | 20 | |
| Age (years) | 48.2 (21–77) | 50.07 (29–72) | 37.4 (23–66) | |
| Gender (M/F) | 16/4 | 10/4 | 12/8 | |
| Time since diagnosis (years) | n/a | 18 (10–33) | 5 (2–14) | |
| Appendectomy | 1 | 1 | 3 | |
| Smoking Status | Current Former Never | 0 4 9 | 6 2 6 | 2 3 9 |
| Medication use | Steroid | n/a | 1 | 12 |
| 5-ASA | n/a | 7 | 8 | |
| Azathioprine | n/a | 4 | 0 | |
| Infliximab | n/a | 0 | 12 | |
| Mean Mayo Score | 0 | 0.25 | 10.3 |
Median copy number/mg and median relative abundance of R. hominis after normalisation for total bacterial copy number in each patient cohort.
| Cohort | n | Median Copy No | IQR | Cohort Comparison | |
|---|---|---|---|---|---|
| HC | 20 | 1.13E + 5 | 3.37E + 5 | HC-QUC | 0.072 |
| QUC | 14 | 1.87E + 5 | 1.03E + 6 | HC-AC | 0.000 |
| AC | 20 | 8.06E + 2 | 5.30E + 3 | QUC – AC | 0.000 |
p values for inter-cohort comparisons.
Figure 2Boxplots representing inter-cohort comparisons of R. hominis. Healthy controls are represented in green, patents with quiescent UC in orange and patients with acute UC in red. * denotes p < 0.05. Loco regional comparison along the longitudinal axis of the colon in the three patient cohorts.
Comparison of R. hominis copy number and relative abundance on a loco-regional basis.
| R. hominis copy no. | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | HC | n | QUC | n | AC | HC-QUC | HC-ACact | QUC-AC | ||||
| Median | IQR | Median | IQR | Median | IQR | |||||||
| Caecum | 16 | 1.00E+5 | 3.75E+5 | 11 | 8.93E+4 | 1.27E+6 | 17 | 1.61E+3 | 4.56E+4 | 0.716 | 0.000 | 0.001 |
| Transverse | 17 | 2.20E+5 | 3.51E+5 | 13 | 8.56E+4 | 2.47E+6 | 16 | 7.62E+2 | 4.85E+3 | 0.869 | 0.000 | 0.000 |
| Left | 15 | 6.57E+4 | 1.85E+5 | 11 | 2.62E+5 | 2.19E+6 | 16 | 8.87E+2 | 2.29E+3 | 0.039 | 0.000 | 0.000 |
| Rectum | 15 | 5.93E+4 | 5.08E+5 | 11 | 2.25E+5 | 9.55E+5 | 16 | 4.64E+2 | 1.46E+3 | 0.305 | 0.000 | 0.000 |
Figure 3Colonisation rates of each bacterial target in each patient cohort. Healthy controls are represented in green, patients with quiescent UC in orange and patients with acute UC in red.
Median copy number/mg and median relative abundance of B. wadsworthia after normalisation for total bacterial copy number in each patient cohort.
| Cohort | n | Median copy No. | IQR | Cohort comparison | |
|---|---|---|---|---|---|
| HC | 20 | 1.18E + 04 | 2.60E + 04 | HC−QUC | 0.546 |
| QUC | 14 | 1.35E + 04 | 3.00E + 04 | HC-AC | 0.000 |
| AC | 20 | 5.05E + 00 | 2.32E + 02 | QUC–AC | 0.000 |
Figure 4Boxplots representing inter-cohort comparisons of B. wadsworthia copy number Healthy controls are represented in green, patients with quiescent UC in orange and patients with acute UC in red. * denotes p < 0.05. Comparison between areas of the colon.
Comparison of B. wadsworthia copy number and relative abundance on a loco-regional basis.
| n | HC | n | QUC | n | AC | HC-QUC | HC-AC | QUC-AC | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | IQR | Median | IQR | Median | IQR | |||||||
| Caecum | 18 | 8.39E + 03 | 1.34E + 04 | 13 | 1.40E + 04 | 2.92E + 04 | 16 | 1.02E + 01 | 1.68E + 02 | 0.590 | 0.000 | 0.000 |
| Transverse | 18 | 1.49E + 04 | 3.20E + 04 | 12 | 9.97E + 03 | 4.92E + 04 | 15 | 5.05E + 00 | 3.27E + 02 | 0.611 | 0.000 | 0.000 |
| Left | 17 | 1.17E + 04 | 3.14E + 04 | 11 | 1.46E + 04 | 3.48E + 04 | 14 | 7.10E + 00 | 1.50E + 03 | 0.869 | 0.000 | 0.001 |
| Rectum | 19 | 1.74E + 04 | 2.86E + 04 | 13 | 7.43E + 03 | 4.14E + 04 | 13 | 1.89E + 00 | 2.02E + 02 | 0.219 | 0.000 | 0.002 |